Patent ID: 8513220

Claim:
A method of treating an immunosuppressant disorder associated with the sphingosine-1-phosphate receptor inhibition, wherein the disorder is selected from rheumatoid arthritis, psoriasis, atherosclerosis, autoimmune uveitis, dry eye, or multiple sclerosis, in a mammal in need thereof, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound represented by Formula I or a pharmaceutically acceptable salt thereof: wherein: R 1 is Me, CF 3 or aryl; R 2 is H, C 1-10 alkyl, or together with R 3 forms a 5 or 6 membered heterocycle ring; R 3 is H, C 1-10 alkyl, or together with R 2 forms a 5 or 6 membered heterocycle ring; R 4 is OPO 3 H 2 , carboxylic acid, C 1-6 alkyl, —S(O) 2 H, —P(O)(OH)(OR 10 ), —P(O)(H)OH or OR 9 ; X is CR 5 or N; Y is CR 6 or N; Z is CR 7 or N; A is O, CH 2 or NR 8 ; L 1 is C 2-10 alkylene; R 5 is H, C 1-10 alkyl, C 2-6 alkenyl or C 3-10 cycloalkyl; R 6 is H, C 1-10 alkyl, C 2-6 alkenyl or C 3-10 cycloalkyl; R 7 is H, C 1-10 alkyl, C 2-6 alkenyl or C 3-10 cycloalkyl; R 8 is H, C 3-10 cycloalkyl or C 1-6 alkyl; R 9 is H or C 1-10 alkyl; R 10 is H or C 1-10 alkyl; Q is C 3-10 cycloalkyl, heterocycle or aryl; and a is 0, 1, 2, 3 or 4; in combination with at least one additional component selected from the group consisting of one or more emulsifying agent, wetting agent, sweetening agent, flavoring agent, tonicity adjuster, preservative, buffer, anti-oxidant and combinations thereof.